Fernando C. Santini

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC

Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski et al. · Cancer Immunology Research · 2018 · 332 citations · Full text

Pharmacy, Immunology, Oncology +17

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion–Positive NSCLC

Caicun Zhou, Benjamin Solomon, Herbert H. Loong et al. · New England Journal of Medicine · 2023 · 213 citations · Full text

Medicine, Oncology, Pharmacology +14

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer

Jamie E. Chaft, Ibiayi Dagogo‐Jack, Fernando C. Santini et al. · Lung Cancer · 2018 · 54 citations · Full text

Medicine, Oncology, Surgery +14

Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy.

Fernando C. Santini, Hira Rizvi, Olivia Wilkins et al. · Journal of Clinical Oncology · 2017 · 52 citations

Medicine, Immunology, Oncology +17

Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced <i>KRAS G12C</i>-Mutant Non–Small Cell Lung Cancer

Rohit Thummalapalli, Ezra Bernstein, Benjamin Herzberg et al. · JCO Precision Oncology · 2023 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17